NCT02599688已完成不适用
An Open-label Extension Study of the Safety and Efficacy of Subconjunctival Liposomal Latanoprost (POLAT-001) in Patients With Ocular Hypertension and Primary Open Angle Glaucoma
Peregrine Ophthalmic1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2015年11月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Intraocular Pressure (IOP)
研究概览
简要总结
This is an open-label, observational extension of patients who received POLAT-001 in LipoLat-CS202.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Intraocular Pressure (IOP)
时间窗: 3 months
Mean change from baseline (Visit 1 in Study LipoLat-CS202, NCT02466399) IOP at Month 3 (6 months after treatment in LipoLat-CS202).
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124HypertensionNCT05459688AstraZeneca175
终止
2 期
An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus ErythematosusLupus Erythematosus, SystemicNCT03407482Genentech, Inc.160
已完成
2 期
Open-Label, Extension Study to 810P202Impulsive Aggression Comorbid With ADHD in ChildrenNCT01416064Supernus Pharmaceuticals, Inc.78
终止
2 期
Open-label Extension Study of Brazikumab in Ulcerative ColitisUlcerative ColitisNCT04277546AstraZeneca57
终止
2 期
A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria TrialsUrticaria ChronicNCT06736262Jasper Therapeutics, Inc.67